PEPGEN INC. Payments to Acquire Marketable Securities
PEPGEN INC. (PEPG) reported Payments to Acquire Marketable Securities of $81.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- PEPGEN INC. payments to acquire marketable securities for the quarter ending 2026-06-30 was $53.49M.
- PEPGEN INC. payments to acquire marketable securities for the quarter ending 2026-03-31 was $28.46M, a 323.12% increase year-over-year.
- PEPGEN INC. payments to acquire marketable securities for the quarter ending 2025-12-31 was $87.25M, a 310.16% increase year-over-year.
- PEPGEN INC. payments to acquire marketable securities for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- PEPGEN INC. payments to acquire marketable securities for fiscal 2025 was $93.97M, a 35.27% decline from fiscal 2024.
- PEPGEN INC. payments to acquire marketable securities for fiscal 2024 was $145.17M, a 393.71% increase from fiscal 2023.
- PEPGEN INC. payments to acquire marketable securities for fiscal 2023 was $29.40M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $53.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $81.94M 10-Q · filed 2026-08-06 | $169.19M derived: sum of 3 quarters · filed 2026-08-06 | $169.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $28.46M 10-Q · filed 2026-05-12 | $115.70M derived: sum of 2 quarters · filed 2026-05-12 | $115.70M derived: sum of 3 quarters · filed 2026-05-12 | $115.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $87.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $87.25M derived: sum of 2 quarters · filed 2026-03-04 | $87.25M derived: sum of 3 quarters · filed 2026-08-06 | $93.97M 10-K · filed 2026-03-04 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $6.73M 10-Q · filed 2025-11-12 | $28.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $6.73M 10-Q · filed 2026-08-06 | $28.00M derived: sum of 3 quarters · filed 2026-08-06 | $57.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.73M 10-Q · filed 2026-05-12 | $28.00M derived: sum of 2 quarters · filed 2026-05-12 | $57.95M derived: sum of 3 quarters · filed 2026-05-12 | $122.66M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $21.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $51.22M derived: sum of 2 quarters · filed 2026-03-04 | $115.93M derived: sum of 3 quarters · filed 2026-03-04 | $145.17M 10-K · filed 2026-03-04 |
| 2024-09-30 | $29.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $94.66M derived: sum of 2 quarters · filed 2025-11-12 | $123.90M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $64.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $93.95M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $29.24M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $29.40M 10-K · filed 2025-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |